Immix Biopharma, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 29, 2024. This is an annual report, not a standalone fourth-quarter report. Immix is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue.
Financial performance and position
| Metric | FY2023 / December 31, 2023 | FY2022 / December 31, 2022 |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $8.74 million | $4.20 million |
| General and administrative expense | $7.41 million | $4.02 million |
| Net loss | $15.60 million | $8.23 million |
| Loss per share, basic and diluted | $0.89 | $0.59 |
| Net cash used in operating activities | $11.37 million | $7.41 million |
| Cash and cash equivalents | $17.51 million | $13.44 million |
| Working capital | Approximately $16.1 million | Not stated here |
| Total liabilities | $3.72 million | $1.75 million |
Operating losses and cash burn increased as the company expanded clinical-trial activity and administrative spending. The filing reports no product revenue, so product margins are not applicable. Cash included $16.11 million in money-market funds. The balance sheet lists current liabilities, principally accounts payable and accrued expenses; it does not show outstanding balance-sheet debt at year-end. A January 2024 manufacturing-space lease is expected to require $1.6 million in payments through December 2033.
FY2023 financing activities provided $15.46 million, mainly from equity and warrant issuance and at-the-market sales. The company reported an accumulated deficit of $53.41 million. The financial statements received an unqualified audit opinion; the auditor did not attest to internal-control effectiveness.
Business, developments, and comparison
- NXC-201: Lead BCMA-targeted CAR-T candidate in the Phase 1b/2a NEXICART-1 trial for relapsed/refractory AL amyloidosis. As reported, 10 AL amyloidosis patients had been treated by the December 2023 data presentation: overall response rate 100% (10/10), complete response rate 70% (7/10), and median CRS duration one day. The cohort is small and early-stage; these findings do not establish safety or efficacy or predict later results.
- The filing also reports 63 relapsed/refractory multiple myeloma patients treated by February 2024 and a 95% overall response rate among patients not previously treated with BCMA-targeted therapy. This is company-reported early clinical data, not an approved indication.
- The FDA granted NXC-201 orphan drug designation for AL amyloidosis in September 2023 and cleared a U.S. IND in November 2023. The European Commission granted orphan designation in February 2024. Management plans to enroll 40 AL amyloidosis patients and pursue a BLA, subject to trial results and regulatory review.
- IMX-110: In Phase 1b/2a development, including combination testing with tislelizumab in colorectal cancer. The filing reports 21 patients treated in the trial by February 2024; analyses included a limited number of evaluable patients. Company-reported soft-tissue sarcoma data included median PFS of four months in U.S. patients and no drug-related serious adverse events observed to date.
- Compared with 2022, FY2023 R&D expense more than doubled, attributed mainly to the ongoing clinical trial and related CRO and patient costs. G&A also increased, including higher professional fees, investor-relations costs, compensation, and stock-based compensation. Interest income rose to $572,006 from zero, reflecting money-market earnings.
- After year-end, the company raised approximately $15.5 million net from a February 2024 public offering and full exercise of the underwriter’s over-allotment option. Management said cash on hand and these proceeds were expected to fund planned operations for at least 12 months from the report date, while noting further capital would be needed beyond that period and could be needed sooner.
Outlook, risks, and unusual items
Management provided no revenue or earnings guidance and expects significant expenses and operating losses to continue. Its stated cash runway depends on estimates and the operating plan; the company has no committed source of additional capital. The filing says continuation as a going concern depends on obtaining financing and achieving profitable operations.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, patient enrollment, dependence on contract manufacturers and other third parties, competition, intellectual-property challenges, reimbursement and market acceptance, and the need for additional financing that could dilute shareholders.
- Nexcella’s license agreement includes approximately $13 million in quarterly payments through September 2026, annual license fees, 5% royalties on licensed-product net sales, potential sales milestones of up to $20 million, and a commitment to fund Israeli NXC-201 trials estimated at approximately $13 million over four years.
- Management identified a material weakness in internal control over financial reporting as of December 31, 2023, related to limited personnel and insufficient formal accounting processes, including journal-entry review. Management described remediation steps begun in 2024; remediation was not assured.
- No material pending legal proceeding was reported. The company reported no cash dividends and does not expect to pay them in the foreseeable future.
Important facts for investors to verify
- Latest cash balance, actual cash burn, and whether the stated runway remains adequate after clinical, licensing, lease, and other commitments.
- Offering proceeds and resulting dilution: reconcile the 2024 net proceeds and post-offering share count with subsequent filings.
- Updated enrollment, follow-up, response durability, organ-response, and safety data for NXC-201; confirm trial design, endpoints, and regulatory feedback before relying on the planned 40-patient path.
- Denominators, follow-up periods, and patient selection behind the company-reported NXC-201 and IMX-110 results, and whether independent or peer-reviewed data support them.
- Progress in remediating the material weakness and whether later filings report effective controls.
- Funding schedule and terms for Nexcella’s license and clinical-trial obligations, and the impact of future financing or potential additional share issuance.